A pilot program in the U.K. that takes selected compounds from pharmaceutical companies’ back catalogues and gathers ideas on their potential scientific use and possible commercial development is being expanded.
The repurposing scheme, begun in 2011 and piloted by AstraZeneca PLC and the U.K.’s Medical Research Council (MRC), is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?